Skip to main content
HNGEHinge Health, Inc.Sell6.4·$67.81-0.79%
Open full analysis

Hinge Health, Inc. (HNGE) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Health Information Services

Sell if holding. Analyst target reached at $67.81 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: partner contracts (82.0%).

Hinge Health delivers AI-powered musculoskeletal care through a digital platform serving self-insured employers, health plans, and Medicare Advantage populations with programs across 16 body areas. Revenue is earned primarily through per-member fees under multi-year contracts;... Read more

$67.81+1.9% A.UpsideScore 6.4/10#1 of 12 Health Information Services
QualityF-score5 / 9FCF yield8.45%
Stop $63.06Target $69.12(analyst − 10%)A.R:R 0.1:1
Analyst target$76.80+13.3%15 analysts
$69.12our TP
$67.81price
$76.80mean
$55
$125

Sell if holding. Analyst target reached at $67.81 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: partner contracts (82.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 6.4/10, moderate confidence.

Passes 6/8 gates (positive momentum, clean insider activity, news boost analyst 0.70, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About Hinge Health, Inc.

About Hinge Health, Inc.

Hinge Health contracted more than 22 million employer lives and served over 60 health plan and PBM partners as of December 31, 2025, making it one of the larger digital MSK platforms by enrolled population. The company expanded its care platform to 16 affected body areas—from neck to ankle—and launched HingeSelect, an in-person MSK care provider network, in 2025. Net losses reached $528.3 million in fiscal 2025, with an accumulated deficit of $1.05 billion since inception.

Hinge Health earns fees from self-insured employers, fully insured health plan populations, and Medicare Advantage plans under contracts averaging three years in length. Eighty-two percent of 2025 revenue flowed through partner agreements with health plans and PBMs, with Health Care Service Corporation (HCSC), Elevance Health (formerly Anthem), and Aetna Life Insurance Company accounting for 17.5%, 13.7%, and 10.5% of revenue, respectively. The AI-powered care model—anchored by TrueMotion motion tracking technology and the FDA-cleared Enso electrical nerve stimulation wearable—reduced human physical therapy hours by an estimated 97% per 2025 internal data. Revenue is recognized ratably over annual subscriptions, and the company is transitioning certain clients to an engagement-based pricing model that could introduce variability in near-term recognized revenue. Most client contracts are three years in length and health plan partner relationships can be unilaterally terminated before expiration.

Show full overview

The three largest health plan partners—HCSC at 17.5%, Elevance at 13.7%, and Aetna at 10.5% of 2025 revenue—each hold contractual ability to unilaterally terminate their agreements per the 10-K. With 82% of revenue running through partner relationships, a loss of any top-three partner could expose Hinge Health to a revenue gap that its 51-person direct employer sales force may take multiple contract cycles to offset. These three partners each individually exceeded 10% of annual revenue in both 2024 and 2025, indicating sustained rather than one-time dependency.

See also: Healthcare · Health Information Services

From Hinge Health, Inc.'s most recent 10-K filing, extracted June 10, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-17
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Aug 4, 202649d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Strong growth profile
Positive momentum
Risks
Concentration risk — Customer: partner contracts (82.0%)
Analyst target reached - limited upside remaining
Near 52-week high (1.3% away)

Key Metrics

P/E (TTM)
P/E (Fwd)20.4
Mkt Cap$5.3B
EV/EBITDA-9.9
Profit Mgn-78.9%
ROE-136.0%
Rev Growth47.2%
Beta
DividendNone
Rating analysts22

Quality Signals

Piotroski F5/9MoatNarrow

Options Flow

P/C0.51bullish
IV60%elevated
Max Pain$80+18.0% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHCustomerpartner contracts82%
    10-K Item 1A: 'Client contracts through our partners accounted for 82% of our revenue for the year ended December 31, 2025'
  • LOWCustomerHCSC18%
    10-K Item 1A: 'client contracts through (i) Health Care Service Corporation ("HCSC") accounted for 17.5% and 17.1% of our revenue, respectively'
  • LOWCustomerElevance14%
    10-K Item 1A: '(ii) Elevance Health, Inc., formerly known as Anthem, Inc. ("Elevance"), accounted for 13.7% and 14.0% of our revenue, respectively'
  • LOWCustomerAetna11%
    10-K Item 1A: '(iii) Aetna Life Insurance Company ("Aetna") accounted for 10.5% and 11.6% of our revenue, respectively'

Material Events(8-K, last 90d)

  • 2026-03-17Item 5.02LOW
    Tyler Sloat appointed as Class I Director effective March 16, 2026; named Chair of Compensation Committee and member of Audit Committee. Previously CFO of Freshworks Inc. (since 2020) and Zuora Inc. No departures cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.0
Value Rank
0.8
Growth Rank
9.2
Industry growth leader

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.9
Support Resistance
1.6
52w Position
9.2
GatesA.R:R 0.1 < 1.5@spotExecutive change: officer departure/appointmentMomentum 7.7>=5.5Insider activity: OKNEWS BOOST ANALYST 0.70EARNINGS PROXIMITY 49d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
81 · Overbought
20D MA 50D MA 200D MAGOLDEN CROSSSupport $52.25Resistance $70.72

Price Targets

$63
$69
A.Upside+1.9%
A.R:R0.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (1.9% upside)
! asymmetry at 0.1 (below the engine's 1.5 threshold)@spot

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-04 (49d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HNGE stock a buy right now?

Sell if holding. Analyst target reached at $67.81 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: partner contracts (82.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $63.06. Score 6.4/10, moderate confidence.

What is the HNGE stock price target?

Take-profit target: $69.12 (+1.9% upside). Prior stop was $63.06. Stop-loss: $63.06.

What are the risks of investing in HNGE?

Concentration risk — Customer: partner contracts (82.0%); Analyst target reached - limited upside remaining; Near 52-week high (1.3% away).

Is HNGE overvalued or undervalued?

Hinge Health, Inc. trades at a P/E of N/A (forward 20.4). TrendMatrix value score: 6.1/10. Verdict: Sell.

What do analysts say about HNGE?

22 analysts cover HNGE with a consensus score of 4.1/5. Average price target: $77.

What does Hinge Health, Inc. do?Hinge Health delivers AI-powered musculoskeletal care through a digital platform serving self-insured employers, health...

Hinge Health delivers AI-powered musculoskeletal care through a digital platform serving self-insured employers, health plans, and Medicare Advantage populations with programs across 16 body areas. Revenue is earned primarily through per-member fees under multi-year contracts; 82% of 2025 revenue was channeled through health plan and PBM partners. The company had over 22 million contracted employer lives and over 60 partners as of December 31, 2025.

Related stocks: WAY (Waystar Holding Corp.) · PRVA (Privia Health Group, Inc.) · VEEV (Veeva Systems Inc.) · HQY (HealthEquity, Inc.) · TEM (Tempus AI, Inc.)
Home Stocks HNGE

Latest news

Latest News

Zacks Investment Research42d ago
MarketBeat42d agoAnalyst
Investing.com Canada42d agoAnalyst
MarketBeat43d ago
Moomoo48d agoEarnings
富途牛牛53d agoAnalyst
MarketBeat46d ago
MarketBeat46d ago
Kalkine Media51d ago
MarketBeat51d ago
Investor's Business Daily44d agoEarnings
TipRanks44d agoEarnings
Investor's Business Daily44d ago
MarketBeat40d ago
The Globe and Mail47d ago
Benzinga2d ago
Benzinga2d agoAnalyst
Benzinga5d ago
Benzinga6d ago
Benzinga6d agoAnalyst
Loading more...